# Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

> **NCT04459078** · PHASE2 · UNKNOWN · sponsor: **Hunan Cancer Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Adenocarcinoma of the Lung

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Albumin Paclitacxel
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04459078
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-26
- **Primary completion:** 2023-05-15
- **Final completion:** 2023-07-15
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2022-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04459078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04459078, "Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04459078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*